Expression of CD36 has been shown to correlate with poor prognosis (disease-free survival and overall survival) in luminal A breast cancer, lung squamous cell carcinoma, bladder cancer and melanoma [29, 45], with studies primarily focusing on the role of CD36 as a receptor for oxidized low density lipoprotein (oxLDL). Here, CD36 is linked to breast cancer.